503 related articles for article (PubMed ID: 26116886)
1. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
Chen PJ; Huang C; Meng XM; Li J
Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
Claveria-Cabello A; Colyn L; Arechederra M; Urman JM; Berasain C; Avila MA; Fernandez-Barrena MG
Cells; 2020 Oct; 9(10):. PubMed ID: 33086678
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
[TBL] [Abstract][Full Text] [Related]
4. Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms.
Khan S; Ahirwar K; Jena G
Epigenomics; 2016 Aug; 8(8):1087-101. PubMed ID: 27411759
[TBL] [Abstract][Full Text] [Related]
5. Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis.
Li X; Wu XQ; Xu T; Li XF; Yang Y; Li WX; Huang C; Meng XM; Li J
Toxicol Appl Pharmacol; 2016 Sep; 306():58-68. PubMed ID: 27396813
[TBL] [Abstract][Full Text] [Related]
6. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
8. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.
Liu Y; Wang Z; Wang J; Lam W; Kwong S; Li F; Friedman SL; Zhou S; Ren Q; Xu Z; Wang X; Ji L; Tang S; Zhang H; Lui EL; Ye T
Liver Int; 2013 Apr; 33(4):504-15. PubMed ID: 23279742
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.
Hyndman KA
Semin Nephrol; 2020 Mar; 40(2):138-147. PubMed ID: 32303277
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin H-Mediated Degradation of HDAC4 for Matrix Metalloproteinase Expression in Hepatic Stellate Cells: Implications of Epigenetic Suppression of Matrix Metalloproteinases in Fibrosis through Stabilization of Class IIa Histone Deacetylases.
Yang Z; Liu Y; Qin L; Wu P; Xia Z; Luo M; Zeng Y; Tsukamoto H; Ju Z; Su D; Kang H; Xiao Z; Zheng S; Duan Z; Hu R; Wang Q; Pandol SJ; Han YP
Am J Pathol; 2017 Apr; 187(4):781-797. PubMed ID: 28157489
[TBL] [Abstract][Full Text] [Related]
11. The potential of HDAC inhibitors as cognitive enhancers.
Gräff J; Tsai LH
Annu Rev Pharmacol Toxicol; 2013; 53():311-30. PubMed ID: 23294310
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis.
Lee CH; Choi Y; Cho H; Bang IH; Hao L; Lee SO; Jeon R; Bae EJ; Park BH
Biochem Pharmacol; 2021 Jan; 183():114312. PubMed ID: 33130126
[TBL] [Abstract][Full Text] [Related]
13. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer.
Zhao J; Gray SG; Greene CM; Lawless MW
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):247-256. PubMed ID: 30791763
[TBL] [Abstract][Full Text] [Related]
14. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of airway inflammation.
Adcock IM; Tsaprouni L; Bhavsar P; Ito K
Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
[TBL] [Abstract][Full Text] [Related]
16. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone deacetylase in thyroid cancer.
Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
Pang M; Zhuang S
J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
[TBL] [Abstract][Full Text] [Related]
19. [EPIGENETIC ENZYMES AS THERAPEUTIC TARGETS FOR TREATING BRAIN DISORDERS].
Gomazkov OA
Eksp Klin Farmakol; 2015; 78(11):35-44. PubMed ID: 27017704
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
